UNIVERSITY HEART & VASCULAR CENTER HAMBURG

A cornerstone of individual cardiovascular risk prediction is the blood concentration of lipoproteins containing apolipoprotein B, particularly non-HDL and LDL cholesterol. The benefit of lipid-lowering strategies has been proven by numerous studies. Today, conventional guidelines recommend the implementation of lipid lowering therapy for cardiovascular primary prevention on the basis of a person's 10-year cardiovascular risk. This risk assessment, however, might fail to take proper account of the personal long-term risk, particularly in younger individuals. As published in The Lancet 2019, we provided the most comprehensive analysis of long-term cardiovascular risk associated with non-HDL cholesterol. On this basis, we developed a risk tool to estimate the individual cardiovascular long-term risk and to calculate the potential long-term benefit of a lipid-lowering strategy in individuals without prevalent cardiovascular disease.

Primary location: Hamburg Germany